[A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
94 patients with obstructive urination due to benign prostatic hyperplasia received finasteride (proscar), inhibitor of 5 alpha-reductase, in a single dose 5 mg and terazosine, alpha 1 adrenoblocker, in a daily dose of 9.7 mg/day. The follow-up averaged 16.1 months. As shown by overall score of the symptoms and quality of life, rectal and ultrasonic examinations, uroflowmetry, the prostate decreased by 17%, on the average in 72% of the patients. Subjectively, urination has also improved. Maximal flow rate elevated by 55% in the majority of patients. Combination of finasterine with terazosine is well tolerated and proved optimal as a conservative therapy in patients with obstructive urination as a result of benign prostatic hyperplasia.
Pushkar'
D Iu
DIu
Kosko
D V
DV
Loran
O B
OB
Kan
Ia D
IaD
Sapozhnikov
I M
IM
Tevlin
K P
KP
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012074:Remission Induction; D013997:Time Factors
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D018120:Finasteride; C041226:Terazosin; D011224:Prazosin
Opyt primeneniia finasterida i terazosina u bol'nykh s dobrokachestvennoĭ giperplazieĭ prostaty.